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Abstract Reactive astrocytes occurring in response to neuro-
degeneration are thought to play an important role in neuronal
regeneration by upregulating the expression of extracellular
matrix (ECM) components as well as the ECM degrading
metalloproteinases (MMPs). We examined the mRNA levels and
cellular distribution of membrane type matrix metalloproteinase
1 (MT1-MMP) and tissue inhibitors 1^4 of MMPs (TIMPs) in
brain stem and spinal cord of wobbler (WR) mutant mice
affected by progressive neurodegeneration and astrogliosis.
MT1-MMP, TIMP-1 and TIMP-3 mRNA levels were elevated,
whereas TIMP-2 and TIMP-4 expression was not affected.
MT1-MMP was expressed in reactive astrocytes of WR. In
primary astrocyte cultures, MT1-MMP mRNA was upregulated
by exogeneous tumor necrosis factor K. Increased plasma
membrane and secreted MMP activities were found in primary
WR astrocytes. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Astrocyte activation, termed reactive gliosis, is a stereotype
reaction of astrocytes to neuronal injury leading to tissue
remodelling and the formation of a glial scar (reviewed in
[1]). A prerequisite for extracellular matrix (ECM) remodel-
ling after neuronal injury is the expression of members of the
family of zinc-dependent matrix metalloproteinases (MMP)
by neurons and astrocytes (reviewed in [2]). Proteinase activity
in turn is regulated by the balance between MMPs, membrane
type MMPs (MT-MMPs) and by tissue inhibitors of metal-
loproteinases (TIMPs) (reviewed in [3]). In models proposed
by Deryugina et al. [4] and Lehti et al. [5], a ternary complex
consisting of MT1-MMP, TIMP-2 and pro-MMP-2 is gener-
ated on the cell surface. Overexpression of MT1-MMP results
in increased pro-MMP-2 processing and subsequent shedding,
whereas active MMP-2 becomes rebound to the plasma mem-
brane by binding to KvL3 integrin [6]. In non-neuronal cells,
the expression of MT1-MMP can be upregulated by tumor
necrosis factor K (TNF-K), indicating its involvement in in-
£ammatory processes [7].
One of the hallmarks of the hereditary wobbler (WR) dis-
ease (wr, chromosome (Chr.) 11) [8] of the mouse is hyper-
trophy of reactive astrocytes and microglia activation in the
white and gray matter of the spinal cord (SC) as indicated by
increased expression of glial ¢brillary acidic protein (GFAP)
and CD45, respectively [9,10]. WR mice are characterized by
progressive neurodegeneration in the thalamus (N. ventralis),
in deep cerebellar nuclei, brain stem (BS) (N. vestibularis), SC
interneurons and large motoneurons [10]. In the course of the
disease, the progressive degeneration of motoneurons results
in muscular atrophy resembling human neurodegenerative dis-
eases like spinal muscular atrophy and amyotrophic lateral
sclerosis [11]. Prior to the onset of astrogliosis, degenerating
motoneurons express pro-transforming growth factor K
(TGFK) followed by the TGFK/epidermal growth factor
(EGF) receptor expression in reactive astrocytes [12]. Since
EGF, which is homologous to TGFK, induces proliferation
and di¡erentiation in cultured astrocytes, it has been specu-
lated that TGFK stimulates astrocyte di¡erentiation in the
WR disease. We and others have described the induction of
proin£ammatory cytokines interleukin-1L and TNF-K in SC
and BS of WR mice [13,14]. However, the target genes of
these cytokines in WR mice were unknown. Therefore, we
investigated the expression of MT1-MMP in mouse mutants
a¡ected by neurodegeneration. In particular, we analyzed the
mechanisms regulating proteinase activity under pathological
conditions in WR mice.
2. Materials and methods
2.1. Materials
Recombinant mouse TNF-K was obtained from Boehringer Bio-
products (Mannheim, Germany), dissolved in sterile phosphate-bu¡-
ered saline (PBS; 140 mM NaCl, 10 mM Na, K phosphate, pH 7.3) to
a concentration of 5 ng/Wl (300 U) and kept in aliquots at 320‡C.
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2.2. Mouse strains
The mouse mutations ‘wobbler’ (wr, WR, Chr. 11) [8,11], ‘motoneur-
on disease’ 2 (mnd2, MND2, Chr. 6; [15]) and ‘muscle de¢cient’ (mdf,
MDF, Chr. 19) [16^18] were kept on a C57BL/6 background. For all
analyses, we used 25^60 day old genotyped WR (wr/wr) or wild-type
(WT) (+/+) [10] individuals or in the case of MND2 and MDF mu-
tant mice, animals with a manifest phenotype and their normal con-
trol littermates. Breeding and experimental use of mice were per-
formed in agreement with the German law on the protection of
animals, with a permit by the local authorities to H.J.
2.3. Cell lines
HEK293 (ACC 305) and HT1080 (ACC 315) cells were obtained
from the German Collection of Microorganisms and Cell Culture
DSMZ (Braunschweig, Germany) and propagated in DMEM/10%
fetal calf serum (FCS). MT1-MMP-transfected HEK293 cells were
kindly provided by Dr. C. Mauch (Cologne, Germany).
2.4. Tissue preparation
For RNA preparation and histological analyses, mice were killed by
decapitation. The central nervous system (CNS) was dissected into
cerebrum (Cbr), comprising telencephalon and diencephalon, and
into cerebellum (Cbl), BS and cervical SC with cervical segments
C1^C8. For cryosections, parts of the CNS were mounted in freezing
medium and rapidly shock frozen in propane/liquid nitrogen.
2.5. Generation of MT1-MMP speci¢c antibodies
Polyclonal antibodies reactive for MT1-MMP were raised in rabbits
against the synthetic peptides PPGDLRTHTQRSPQSLS(C) and
CDGNFDTVAMLRGEM corresponding to the propeptide (K-PD)
and hemopexin-like domains (K-HD), respectively (Fig. 2A). The pep-
tides were conjugated to keyhole limpet hemocyanin via an additional
cysteine residue.
2.6. Preparation of plasma membrane-enriched cell fractions
CNS tissue samples (300 mg) were homogenized in 4 ml 8.7% (w/v)
sucrose in 20 mM Tris^HCl pH 7.4 containing proteinase inhibitors
(‘complete EDTA-free’; Roche, Mannheim, Germany) on ice and
loaded onto 9 ml of 38% (w/v) sucrose in 20 mM Tris^HCl pH 7.4.
Following centrifugation at 150 000Ug for 1 h at 4‡C, the enriched
plasma membrane fraction was isolated from the interphase and di-
luted in 8.7% (w/v) sucrose solution. The plasma membranes were
pelleted again at 150 000Ug for 1 h at 4‡C, resuspended in 68 mM
Tris^HCl pH 6.8 and stored at 370‡C. The amount of protein in the
plasma membrane preparation was estimated according to Bradford
(modi¢ed, [19]).
2.7. Immunoblotting
30 Wg of enriched plasma membrane fractions were solubilized in
Laemmli bu¡er at room temperature, subsequently boiled and sepa-
rated by 10% sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE) [20]. Proteins were transferred to nitrocellulose by
electroblotting. Following blocking with PBS/5% non-fat dry milk, the
membrane was incubated with 10 Wg/ml of rabbit anti-MT1-MMP-
HD or anti-MT1-MMP-PD for 16 h at 4‡C. After extensive washing,
the membrane was incubated with goat anti-rabbit IgG coupled to
horseradish peroxidase and developed with the ECL Western blot
detection kit (Amersham Pharmacia Biotech, Heidelberg, Germany).
2.8. Immunocytochemistry
Cryosections of CNS tissues, usually 10 Wm in thickness, were ¢xed
for 5 min with ice-cold methanol or acetone, washed three times with
PBS and blocked with PBS/0.5% bovine serum albumin (BSA). For
double labeling, cryosections were incubated with MT1-MMP speci¢c
rabbit antibodies (10 Wg/ml in PBS/0.5% BSA) and with a monoclonal
Cy3-conjugated anti-GFAP antibody (1:800; Sigma, Deisenhofen,
Germany) or Cy3-conjugated anti-CD45 (1:200, clone 30F11.1, Phar-
mingen), followed by the incubation with goat-anti rabbit Cy2-con-
jugated antibodies (1:500; Dianova, Hamburg, Germany).
2.9. Astrocyte cultures
CNS from animals killed by decapitation was removed immediately
and dissected into Cbl, BS and SC. Samples were kept in HEPES-
bu¡ered saline (pH 7.6) and mechanically dissociated with scissors.
The homogenates were further minced by triturating with an 18 gauge
needle and incubated for 10 min with 0.25% trypsin/EDTA (Gibco
BRL, Karlsruhe, Germany). After centrifugation, the cell pellet was
resuspended in astrocyte basal medium (Clonetics, La Jolla, CA,
USA) containing 5% FCS and insulin (1 Wg/ml). Cells were seeded
onto type I collagen (Sigma) coated coverslips. Medium was changed
every second day and cell cultures were used for all assays usually
after 7 days. The proportions of astrocytes in cell preparations were
determined by anti-GFAP staining. Preparations with v90% GFAP
cells were used for all further experiments.
2.10. Reverse transcription (RT) and polymerase chain reaction
(PCR)
Total RNA from tissues was puri¢ed according to Chomczynski
and Sacchi [21]. For mRNA isolation, total RNA was further puri¢ed
by the Dynabead method (Dynal, Hamburg). From primary cell cul-
tures, total RNA was isolated by the RNeasy preparation method
(Qiagen, Hilden, Germany). For RT-PCR, either 1 Wg of total
RNA or 100 ng of mRNA in 20 Wl was reverse-transcribed using
SuperScript reverse transcriptase (Life Technologies GmbH, Eggen-
stein, Germany). 0.2 Wl of the RT mixture was used for PCR ampli-
¢cation in a total volume of 20 Wl containing 1 Wmol of each primer
(see Table 1) and ‘Master-Mix’ (Qiagen, Hilden, Germany). Primers
were obtained from TIB MolBiol (Berlin, Germany) and are listed in
Table 1. Semi-quantitative PCRs were performed by applying a vary-
ing number of the following PCR cycles (10^20 cycles): 4 min 94‡C
(pre-PCR), followed by 1 min at the annealing temperature, 1 min
72‡C and 1 min 92‡C. The resulting ampli¢cation products (see Table
1) were separated by electrophoresis on 2% agarose gels and visualized
with ethidium bromide. Ethidium bromide-stained ampli¢cation prod-
ucts were blotted onto nitrocellulose, hybridized with a [K-32P]dATP
random prime labeled gene speci¢c probe and quanti¢ed with a Bio-
Imager (Bio-Rad, Go«ttingen, Germany). Probes were obtained by
cloning the respective PCR fragments in pTOPO (Invitrogen) and
veri¢ed by DNA sequencing. Quanti¢cation and analysis of the
RT-PCR products were performed on the basis of the standard log
plots of hybridization signals versus cycle number (data not shown).
RT-PCR experiments were usually performed with 20 cycles, the
cDNAs were standardized to an equal level of cDNA for the house-
keeping gene L7 [22].
2.11. Immunolocalization of MT1-MMP on cultured astrocytes
After 7 days in culture, primary astrocytes were used for immuno-
Table 1
Primers used for RT-PCR analyses of MT1-MMP, TIMPs 1^4 and L7
Name Orientation Sequence Length (bp) Temperature (‡C)
MT1-MMPmet sense 5P-CCTCGCTGTGGTGTTCCGGAT-3P 458 64
antisense 5P-ATGCCCCAACTCATGCAGAGC-3P
TIMP-1 sense 5P-CCTTTGCATCTCTGGCATCTGGCA-3P 437 68
antisense 5P-CCAACAGCCAGCACTATAGGTGTT-3P
TIMP-2 sense 5P-GGACCTGACAAAGACATCGAGTT-3P 348 68
antisense 5P-TCTCTTGATGCAGGCGAAGAAC-3P
TIMP-3 sense 5P-CCCTTTGGCACTCTGGTCTACA-3P 374 68
antisense 5P-TTTGGACTGATAGCCAGGGTACC-3P
TIMP-4 sense 5P-CCAGTGAGAAAGTAGTCCCTG-3P 461 62
antisense 5P-GCTGCAGATGCCATCAACATG-3P
L7 sense 5P-AGATGTACCGCACTGAGATCC-3P 352 62
antisense 5P-ACTTACCAAGAGACCGAGCAA-3P
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£uorescence microscopy studies. Cells were rinsed extensively with
PBS/0.5 mM CaCl2 and ¢xed with PBS/2% (w/v) paraformaldehyde
at room temperature. After incubation with PBS/0.5 mM CaCl2/2%
(w/v) BSA for 45 min at 4‡C, cells were preincubated with the rat
monoclonal anti-FcQRII speci¢c antibody 2.4G2 (25 Wg/ml) for 30 min
at 4‡C [23]. Samples were incubated with mouse monoclonal anti-
MT1-MMP antibody 113-5B7 (40 Wg/ml; Fuji Chemical Industries)
[24] in the presence of 2.4G2 for 2 h at 4‡C. After washing with PBS/
0.5 mM CaCl2, cells were incubated with Cy2-conjugated goat anti-
mouse polyclonal antibody (Dianova, Hamburg, Germany) for 1 h,
washed again and mounted on glass slides with Mowiol 4-88
(Hoechst).
2.12. Determination of MMP activity
To determine the activity of astrocyte plasma membrane-associated
and -secreted MMPs, 7 day old astrocyte cultures grown on 3.5 cm
tissue culture dishes were washed and incubated for 12 h in 2.5 ml
HEPES-bu¡ered saline containing 5 mM glucose. The conditioned
medium obtained from 5U105 cells was collected and immediately
analyzed. Cells were detached with PBS containing 10 mM glucose
and resuspended in 2.5 ml 10 mM HEPES bu¡er. Supernatant and
cells were incubated with 500 nmol of the £uorogenic peptide Mca-
Pro-Leu-Gly-Leu-Dap-(Dnp)-Ala-Arg-NH2 (Bachem, Heidelberg) for
1 h at 37‡C in the dark, in a total volume of 2.5 ml [25]. Subsequently,
cells were pelleted and the supernatant was analyzed on a Perkin
Elmer Luminescence Spectrometer L55OB. The proteolytic activity
towards the Gly-Leu bond was determined as an increase in the £uo-
rescence intensity following excitation at 328 nm and detection of
emission at 393 nm.
3. Results
3.1. Levels of mRNAs for MT1-MMP and TIMP-1, 2, 3 and
4 in the CNS of WT and WR mice
Total RNA from Cbr, BS, Cbl, SC and testis (as non-CNS
control tissue) of 40 day old WT and WR mice was subjected
to RT-PCR with speci¢c primer pairs (Table 1 and Fig. 1A).
Using 30 PCR cycles, MT1-MMP expression was detectable
in all CNS regions of WR mice, whereas expression was low
in Cbr, BS and SC of WT controls (Fig. 1A). Ampli¢cation
under non-saturating conditions (20 cycles) revealed altered
mRNA levels of MT1-MMP and TIMP-1^4 in a¡ected WR
mice and are given as the ratio of the amounts of ampli¢cates,
Fig. 1. mRNA levels of MT1-MMP and TIMPs 1^4 in di¡erent CNS regions and in testis of WT and WR mice. A: Ethidium bromide-stained
gel of PCR products following RT and ampli¢cation for 30 cycles. The mRNA for L7 ribosomal protein was used as reference (for sizes of
ampli¢cates, see Table 1). NC, control (no template). B: mRNA levels (20 cycles) in WR as compared to WT mice. The amount of radioactiv-
ity in imager units normalized to the L7 reference signal is given as ratio WR to WT. Signals are the mean values of four independent experi-
ments. Asterisk, no signal detected. Abbreviations used: Cbr, cerebrum; BS, brain stem; Cbl, cerebellum; SC, spinal cord; Tes, testis.
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WR to WT (Fig. 1B). MT1-MMP expression in WR mice was
upregulated predominantly in BS, Cbl and SC, whereas ex-
pression in the Cbr and testis remained unchanged. Maximal
upregulation of the MT1-MMP transcript was observed in
the BS (about ¢ve-fold). The highest expression of MT1-
MMP was found in most severely a¡ected CNS regions in
WR mice.
In WR mice, elevated mRNA levels were also found with
TIMP-1 and TIMP-3, whereas the mRNA levels of TIMP-2
and TIMP-4 were una¡ected by the disease. TIMP-1, TIMP-2
and TIMP-3 expression was detectable in all tissues tested
(Fig. 1A). TIMP-4 was highly expressed in CNS, but unde-
tectable in testis (Fig. 1A). TIMP-1 expression was 15-fold
increased in BS and 23-fold in SC. Likewise, we observed a
tissue-dependent increase in TIMP-3 expression, with highest
expression in WR mouse Cbl (12-fold increase, Fig. 1C).
3.2. Increased MT1-MMP protein level in the CNS of the WR
mouse
Two polyclonal antibodies reactive to the propeptide (K-
PD) and hemopexin-like domain (K-HD) of MT1-MMP
were raised in rabbits (Fig. 2A). Plasma membrane-enriched
protein extracts from WT and WR CNS were prepared and
probed with K-HD (Fig. 2B). As a control, plasma membrane
extracts from untransfected and MT1-MMP-transfected
HEK293 cells and HT1080 cells were probed with K-HD.
The antibody predominantly recognized a 60 kDa band in
plasma membrane preparations from MT1-MMP expressing
HEK293 cells, HT1080 cells and CNS extracts. The immuno-
blot also revealed staining of lower Mr proteins that may be
degradation products of the 60 kDa protein. The antibody
also reacted with a 63 kDa protein in plasma membrane ex-
tracts from HT1080 cells which corresponds to the unpro-
cessed form as indicated by probing with K-PD. The K-PD
further reacted with a protein of approximately 67 kDa, that
may be a precursor form of mature MT1-MMP. Like mRNA
levels, protein levels of MT1-MMP were higher in WR than in
WT CNS. The predominant form expressed in both WT and
WR CNS was the 60 kDa form, i.e. the catalytically active
MT1-MMP, whereas faint staining was observed for proteins
of 63 kDa and 67 kDa.
3.3. MT1-MMP is expressed in reactive astrocytes
To determine the cellular expression pattern of MT1-MMP
SC cryosections of WT and WR mice were probed with MT1-
MMP speci¢c antibodies (Fig. 3A^E) and anti-GFAP mono-
clonal antibody (Fig. 3E,F). Strong GFAP immunostaining
was seen with SC sections of 60 day old WR mice but not
in age-matched WT mice (Fig. 3E,F, respectively), indicating
a strong astrogliosis [9]. Both MT1-MMP speci¢c antibodies,
K-PD and K-HD, intensely stained the gray matter in SC
sections of WR mice (Fig. 3B,D), whereas WT mice revealed
only occasional staining (Fig. 3A,C). MT1-MMP K-PD and
K-HD positive cells displayed the typical morphological as-
pects of astrocytes with long branched processes. Comparison
of the number of cells stained with K-PD or K-HD revealed a
lower amount of K-PD immunoreactive cells indicating the
expression of active MT1-MMP. MT1-MMP immunoreactive
cells from WR SC were identi¢ed as astrocytes by double
immunohistochemical staining with K-GFAP and K-HD
(Fig. 3, lower panel). Microglia identi¢ed by K-CD45 staining
were morphologically distinct from astrocytes and revealed
only occasional faint staining with K-HD in SC sections
from WR mice (Fig. 3, lower panel).
3.4. MT1-MMP expression is elevated in the CNS of mouse
mutants with neurodegeneration
To demonstrate the coincidence of MT1-MMP expression
with the occurrence of reactive astrocytes in the SC, we
stained SC sections of two additional mouse mutants, MDF
(mdf) [16^18] and MND2 (mnd2) [15], with K-HD. In these
like in WR, degeneration of motoneurons in the ventral horn
is accompanied by local activation of astrocytes as judged by
K-GFAP staining. In both mutants, reactive astrocytes express
MT1-MMP (Fig. 4). This ¢nding supports the notion that
upregulation of MT1-MMP is a common feature of reactive
astrocytes responding to neurodegeneration.
Fig. 2. Generation of MT1-MMP speci¢c antibodies and immuno-
detection of MT1-MMP in Western blots. A: Domain organization
of MT1-MMP and schematic representation of the immunogenic
peptides used to raise the polyclonal pro-domain (K-PD) and the he-
mopexin-like domain (K-HD) antibodies. Amino acid numbering re-
fers to the deduced amino acid sequence of human MT1-MMP be-
ginning with the proposed start methionine (GenBank accession No.
D26512). B: Antigen signals of MT1-MMP in CNS plasma mem-
brane preparations from WT and WR mice. Plasma membrane-en-
riched protein extracts (30 Wg per lane) were separated by 10%
SDS^PAGE, electroblotted and probed with K-HD. Plasma mem-
brane extracts of HEK293 cells (293), MT1-MMP-transfected
HEK293 cells (293-MT1) and HT1080 were used as controls and
probed with K-HD. HT1080 protein extracts were further probed
with K-PD to determine the identity of the 63 kDa form. Arrows
indicate MT1-MMP immunoreactive proteins. The upper arrow cor-
responds to latent MT1-MMP (63 kDa), the lower arrow to the ac-
tive form (60 kDa) identi¢ed by incubating HT1080 protein extracts
with K-PD.
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3.5. MT1-MMP and MMP upregulation in primary astrocyte
cultures from WR mice
To determine the expression pattern of TIMPs and MT1-
MMP in astrocytes, primary astrocytes derived from a¡ected
CNS regions of WT and WR mice were cultured and analyzed
during a 7 day culture period in which the cells developed
extensive branches (Fig. 5C). Astrocytes from WT and WR
mice express TIMP-2 as shown by semi-quantitative RT-PCR,
whereas the expression of TIMP-1 and TIMP-3 was relatively
low (Fig. 5A,B). This result implies that astrocytes may not be
the main source of TIMP-1 and TIMP-3 in SC extracts. Since
primary astrocytes from rat brain reportedly express TIMP-1
and TIMP-3, regional e¡ects may in£uence the repertoire of
TIMPs expressed [26]. Despite high expression levels of
TIMP-4 in SC, primary astrocyte cultures did not express it
(Fig. 5A). A 10-fold upregulation was found for MT1-MMP
mRNA levels in primary astrocytes derived from WR as com-
pared to control mice (Fig. 5A,B).
To analyze the cellular localization of MT1-MMP in pri-
mary astrocytes, cells attached to collagen type I coated cover-
slips were stained with MT1-MMP speci¢c mouse monoclonal
antibody 113-5B7 [24]. In WT astrocytes, MT1-MMP was not
detectable (data not shown). MT1-MMP immuno£uorescence
staining of WR astrocytes resulted in a speckled labeling of
the plasma membrane along the astrocyte processes (Fig. 5C).
Using the MMP peptide substrate, Mca-Pro-Leu-Gly-Leu-
Dap-(Dnp)-Ala-Arg-NH2 [25], we found a signi¢cant increase
in cell-bound and secreted proteolytic activity in primary as-
trocytes from WR mice (Fig. 5D).
3.6. TNF-K inducible MT1-MMP expression in primary
astrocytes
As demonstrated for HT1080 cells, the proin£ammatory
Fig. 4. Immunohistochemical staining of MT1-MMP with K-HD in
mouse mutants with motoneuron degeneration in the ventral horn
of the SC (white matter to the right). A: WT (C57BL/6), 40 days;
B: MDF mutant, 40 days; C: WT (C57BL/6), 30 days; D: MND2
mutant, 30 days. Parallel stainings with anti-GFAP antibody (not
shown) revealed that the labeled cells are reactive astrocytes. Bar in
A, 30 Wm.
Fig. 3. MT1-MMP in the SC of WT (left, A, C, E) and WR (right,
B, D, F) mice. Cervical SC sections (ventral horn) from 60 day old
mice were stained with antibodies reactive for the pro-domain (K-
PD, A and B) and the hemopexin-like domain (K-HD, C and D).
For identi¢cation of astrocytes, sections were stained in parallel
with anti-GFAP antibody (E and F). For cell type identi¢cation,
WR SC sections were double-stained for GFAP/MT1-MMP (K-HD)
or CD45/MT1-MMP (K-HD). Bar in A, 10 Wm, valid for A to F;
bars in lower panel, 25 Wm.
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cytokine TNF-K is an important regulator of MT1-MMP ex-
pression [7]. As TNF-K is one of the major cytokines induced
in a¡ected CNS regions of WR mice [13], we determined
mRNA levels of MT1-MMP in WT and WR astrocyte cul-
tures by semi-quantitative RT-PCR in response to recombi-
nant mouse TNF-K. A dose-dependent upregulation of MT1-
MMP expression in WT mice (approximately six-fold) was
found, while MT1-MMP expression in WR mice remained
unchanged (Fig. 6).
4. Discussion
In the CNS, an increase in active MT1-MMP and MMP-2
with subsequent local ECM degradation is a key event for
tumor progression and invasion of malignant gliomas. In ad-
dition, altered levels of MMPs and TIMPs have been impli-
cated in CNS diseases, such as Alzheimer disease and multiple
sclerosis [2]. Neuroin£ammatory signals a¡ect the level of
Fig. 5. Expression of MT1-MMP and TIMP-1^4 in primary astrocyte cultures from WT and WR mice. A: mRNA levels of MT1-MMP,
TIMP-1^4 and L7 were analyzed as described in Section 2. NC, without template. B: Evaluation of MT1-MMP and TIMP mRNA levels
expressed as WR to WT ratio. C: Seven day old astrocyte culture from WR mice ¢xed with paraformaldehyde and stained with MT1-MMP
speci¢c monoclonal antibody 113-5B7 (insert in C, phase contrast w/o ¢xation). Bar in C, 50 Wm. D: Cell-associated (‘cells’) and secreted (‘me-
dium’) proteolytic activity in primary astrocyte cultures determined by cleavage of the £uorogenic Mca-peptide. Fluorescence intensity units
(excitation at 328 nm, emission at 393 nm) after background subtraction (Mca-peptide incubated without protein). Data from two independent
experiments in each of which cultures were pooled preparations from three WR and from three WT mice. Error bars represent the maximum
deviation from the mean.
Fig. 6. Levels of MT1-MMP mRNA in primary astrocyte cultures
from WT and WR mice in response to TNF-K. Astrocyte cultures
were treated for 24 h with recombinant mouse TNF-K at the indi-
cated concentrations. The mRNA levels of MT1-MMP were deter-
mined by radioactive hybridization of PCR products (see Section 2).
Mean values of three independent experiments þ S.D.
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TIMP-1 and MT1-MMP in transgenic animal models express-
ing TNF-K under the control of the astrocyte speci¢c GFAP
promotor [27]. However, the role of MT1-MMP and TIMPs
in progressive neurodegenerative diseases has been elusive.
We show that concomitantly with neurodegeneration in the
CNS of WR mice, MT1-MMP expression is upregulated 3^5-
fold at the mRNA level. MT1-MMP speci¢c antibodies
stained reactive astrocytes in the WR SC but not microglia.
In contrast, in Alzheimer’s disease brain white matter micro-
glia express MT1-MMP [28]. These results might re£ect diver-
gent pathways for microglia activation in di¡erent neurolog-
ical disorders.
Immunoblot analysis of CNS extracts revealed a major
band of 60 kDa which most likely corresponds to the active
form of MT1-MMP [7]. Comparison of the immuno£uores-
cence staining using K-HD with K-PD revealed a higher label-
ing with the K-HD antibody, which recognizes both the pro-
and active form. Therefore, a major proportion of MT1-
MMP detected in cryosections corresponds to the processed
form, although a signi¢cant amount represents the proform.
The di¡erence in the amount of proform detected in plasma
membrane extracts and cryosections may in part be due to
partial degradation during preparation of plasma membrane
fractions despite the presence of protease inhibitors. A much
higher proportion of active MT1-MMP has been detected in
human astrocytic tumors and C6 glioma cells which were
associated with enhanced MMP-2 processing activity [29,30].
In our study, we found both an increased cell-associated pro-
teolytic activity of WR astrocytes as compared to WT, and an
increase in the amount of secreted MMPs. Thus, the enhanced
expression of MT1-MMP in WR astrocytes correlates with an
increase in secreted activated MMPs.
Along with upregulated MT1-MMP expression, TIMP-1
mRNA levels were drastically increased in WR SC and BS,
while TIMP-2 was constitutively expressed in both WT and
WR mice. In WR mice, there was a regional di¡erence in the
expression pattern of TIMP-1 and TIMP-3 with a higher in-
crease in TIMP-3 mRNA levels in the Cbl and BS compared
to the SC. Our results on TIMP expression suggest that
TIMP-1 and TIMP-3 may regulate the activities of di¡erent
MMPs in distinct regions of the CNS. Unlike TIMP-1 and
TIMP-2, TIMP-3 is stored in the ECM [31]. Because TIMP-3
like TIMP-2 [32] is capable to control the activity of MT1-
MMP, it could also provide a control of the activities of
secreted MMPs as well as of MT1-MMP. Furthermore,
TIMP-3 has been shown to inhibit ADAM10 and the TNF-
K processing enzyme TACE [33,34]. The proin£ammatory cy-
tokine TNF-K is highly expressed in reactive glia in WR CNS
compared to WT mice [13] and the MT1-MMP expression of
primary astrocyte cultures from WT is strongly induced by
TNF-K, whereas MT1-MMP expression of WR-derived astro-
cytes cannot be further augmented in response to TNF-K,
presumably because it is already activated. These results point
to TNF-K as an important regulator of astrogliosis and asso-
ciated MT1-MMP overexpression [13]. Furthermore, TNF-K
is a known inductor for TIMP-1 expression in astrocytes and
brain endothelial cells [26]. TIMP-1 has been reported to con-
trol the activity of MMP-3 and MMP-9 [35,36]. In normal
adult mice, TIMP-1, MMP-3 and MMP-9 expression in the
brain is low, but upregulated in response to tissue injury,
in£ammation and malignant tumors [27,37^39]. The novel
¢nding is that in addition to TIMP-1, also TIMP-3 is tran-
scriptionally upregulated in a neurodegenerative disease.
Compared to TIMP-2 mRNA levels and to the expression
pro¢les in CNS extracts, TIMP-1 and TIMP-3 expression in
primary astrocytes from both WR and WT mice was relatively
low. Thus, reactive astrocytes are probably not the main
source of the elevated TIMP-1 and TIMP-3 expression,
although we cannot rule out that primary astrocyte cultures
cease to produce TIMPs.
In primary astrocyte cultures, MT1-MMP speci¢cally local-
izes to outgrowing processes. MT1-MMP expression may thus
facilitate the breakdown of glia inhibitory proteins, such as
tenascin and the high molecular weight myelin protein NI-
220, thus enabling astrocytes to have access to the sites of
motoneuron degeneration. MT1-MMP by itself has been de-
scribed to cleave various ECM components such as laminin-5
and collagen [40]. It has recently been shown that the migra-
tion of epithelia cells over laminin-5 is dependent on MT1-
MMP expression [41]. MT1-MMP expression on reactive as-
trocytes may facilitate neuronal regeneration and aid axonal
outgrowth.
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